Story
COLCAP Index Slips as Financial and Utility Stocks Weigh on Colombian Market

Summary
Colombia's benchmark COLCAP index ended Tuesday's session lower, falling 0.80% amid broad-based declines led by the financial, investment, and public services sectors. State-owned oil company Ecopetrol was a notable outperformer, bucking the negative trend.
Colombia's benchmark COLCAP index closed down 0.80% on Tuesday, as weakness in the financial and public services sectors weighed on the broader market. The decline came despite gains in some key commodity-linked stocks, according to data reported by Investing.com.
Sector and Stock Performance
The slide in the COLCAP was primarily driven by losses across several key industries. The financial, COL Investment, and public services sectors were cited as the main drivers behind the index's negative performance.
Among the session's most significant decliners were:
- Etb (BVC:ETB): fell 3.70% to close at 130.00.
- Interconnection Electric SA ESP (BVC:ISA): dropped 2.86% to 29,160.00.
- Grupo Argos SA (BVC:GRUPOARGOS): declined 2.60% to 21,720.00.
AdBucking the downward trend was the state-controlled oil company Ecopetrol (BVC:ECOPETROL), which emerged as the day's top performer. The stock rose 2.92% to finish the session at 2,820.00. Other notable performers included Grupo Cibest SA (BVC:CIBEST), which edged up 0.02%.
Broader Market Context
In currency markets, the Colombian Peso showed slight strength against the U.S. dollar, with the USD/COP pair falling 0.12% to 3,335.17. The move occurred even as the U.S. Dollar Index, which measures the greenback against a basket of major currencies, rose 0.20%.
Commodity futures, which can influence investor sentiment in resource-rich economies like Colombia, saw mixed results. December contracts for U.S. C-type coffee rose 1.37%, while U.S. cocoa futures for the same month fell sharply by 4.20%. Meanwhile, December gold futures gained 1.11% to trade at $4,214.85.
Read next
More on Stocks
Dyne Therapeutics Shares Rise on Positive 12-Month Data for DM1 Drug
The clinical-stage biotech company reported significant functional improvements in patients with myotonic dystrophy type 1 (DM1) in its Phase 1/2 ACHIEVE trial, boosting investor confidence.

Accelevation Prices IPO at $18 Per Share Ahead of Nasdaq Debut
Accelevation Holdings Corp. has priced its initial public offering of 30 million shares at $18.00 each, with the majority of shares being sold by existing stockholders. The company is set to begin trading on the Nasdaq under the ticker ACCV.

TSA to Remove Chairs from Airport ID Checkpoints, Drawing Union Criticism
The Transportation Security Administration will require its officers to stand while checking IDs at US airports, a move the agency says enhances security but a major union decries as a disregard for worker safety.

Robinhood to Introduce 24/7 Trading with Weekend Access for Select US Stocks
The online brokerage announced it will allow users to trade a selection of US stocks and ETFs around the clock on weekends, a first for the platform and part of a broader industry shift toward continuous market access.